152 related articles for article (PubMed ID: 20499132)
1. LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells.
Maia RC; Vasconcelos FC; de Sá Bacelar T; Salustiano EJ; da Silva LF; Pereira DL; Moellman-Coelho A; Netto CD; da Silva AJ; Rumjanek VM; Costa PR
Invest New Drugs; 2011 Dec; 29(6):1143-55. PubMed ID: 20499132
[TBL] [Abstract][Full Text] [Related]
2. The pterocarpanquinone LQB 118 induces apoptosis in tumor cells through the intrinsic pathway and the endoplasmic reticulum stress pathway.
de Sá Bacelar T; da Silva AJ; Costa PR; Rumjanek VM
Anticancer Drugs; 2013 Jan; 24(1):73-83. PubMed ID: 22960938
[TBL] [Abstract][Full Text] [Related]
3. NFκB pathway and microRNA-9 and -21 are involved in sensitivity to the pterocarpanquinone LQB-118 in different CML cell lines.
de Faria FC; Leal ME; Bernardo PS; Costa PR; Maia RC
Anticancer Agents Med Chem; 2015; 15(3):345-52. PubMed ID: 25964959
[TBL] [Abstract][Full Text] [Related]
4. The therapeutical potential of a novel pterocarpanquinone LQB-118 to target inhibitor of apoptosis proteins in acute myeloid leukemia cells.
de Souza Reis FR; de Faria FC; Castro CP; de Souza PS; da Cunha Vasconcelos F; Bello RD; da Silva AJ; Costa PR; Maia RC
Anticancer Agents Med Chem; 2013 Feb; 13(2):341-51. PubMed ID: 22721384
[TBL] [Abstract][Full Text] [Related]
5. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
Oncotarget; 2017 May; 8(18):29679-29698. PubMed ID: 27557509
[TBL] [Abstract][Full Text] [Related]
6. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
[TBL] [Abstract][Full Text] [Related]
7. The pterocarpanquinone LQB-118 inhibits tumor cell proliferation by downregulation of c-Myc and cyclins D1 and B1 mRNA and upregulation of p21 cell cycle inhibitor expression.
Martino T; Magalhães FC; Justo GA; Coelho MG; Netto CD; Costa PR; Sabino KC
Bioorg Med Chem; 2014 Jun; 22(12):3115-22. PubMed ID: 24794748
[TBL] [Abstract][Full Text] [Related]
8. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
9. 11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes.
Lemos LG; Nestal de Moraes G; Delbue D; Vasconcelos Fda C; Bernardo PS; Lam EW; Buarque CD; Costa PR; Maia RC
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2119-30. PubMed ID: 27520309
[TBL] [Abstract][Full Text] [Related]
10. Insights into the Biological Evaluation of Pterocarpanquinones and Carbapterocarpans with Anti-tumor Activity against MDR Leukemias.
Rumjanek VM; Maia RC; Salustiano EJ; Costa PRR
Anticancer Agents Med Chem; 2019; 19(1):29-37. PubMed ID: 29692266
[TBL] [Abstract][Full Text] [Related]
11. The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress.
Martino T; Kudrolli TA; Kumar B; Salviano I; Mencalha A; Coelho MGP; Justo G; Costa PRR; Sabino KCC; Lupold SE
Prostate; 2018 Feb; 78(2):140-151. PubMed ID: 29105806
[TBL] [Abstract][Full Text] [Related]
12. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
13. Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
Liao HC; Chou YJ; Lin CC; Liu SH; Oswita A; Huang YL; Wang YL; Syu JL; Sun CM; Leu CM; Lin CH; Fu SL
Biochem Pharmacol; 2019 May; 163():308-320. PubMed ID: 30822403
[TBL] [Abstract][Full Text] [Related]
14. The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets FoxO3a and FoxM1 transcription factors.
Nestal de Moraes G; Castro CP; Salustiano EJ; Dumas ML; Costas F; Lam EW; Costa PR; Maia RC
Int J Oncol; 2014 Nov; 45(5):1949-58. PubMed ID: 25174716
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
16. The LQB-223 Compound Modulates Antiapoptotic Proteins and Impairs Breast Cancer Cell Growth and Migration.
Lemos LGT; Longo GMDC; Mendonça BDS; Robaina MC; Brum MCM; Cirilo CA; Gimba ERP; Costa PRR; Buarque CD; Nestal de Moraes G; Maia RC
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614718
[TBL] [Abstract][Full Text] [Related]
17. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
[TBL] [Abstract][Full Text] [Related]
18. Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Ozkan T; Hekmatshoar Y; Karabay AZ; Koc A; Altinok Gunes B; Karadag Gurel A; Sunguroglu A
Leuk Res; 2021 Mar; 102():106523. PubMed ID: 33607534
[TBL] [Abstract][Full Text] [Related]
19. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
[TBL] [Abstract][Full Text] [Related]
20. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Wong SM; Liu FH; Lee YL; Huang HM
PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
